Bibliographical noteFunding Information:
Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu) and from the Swedish BioFINDER study. A complete list of BioFINDER members can be found at http://biofinder.se/the_biofinder_ study_group/. The BioFinder study was supported by the European Research Council, the Swedish Research Council, the Swedish Brain Foundation, the Swedish Alzheimer Association, the Marianne and Marcus Wallenberg Foundation, the Skåne University Hospital Foundation, and the Swedish federal government under the ALF
agreement. ADNI data collection and sharing for this project was funded by ADNI grants [(National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012)]. ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.
The present study was funded by a grant from the Alzheimer Forschung Initiative e.V. to M.J.G. (grant number #16037), and NIH grants 1K23EB019023 and R01AG052653-01A1 to J.S. M.S. is supported by the Knut and Alice Wallenberg Foundation, the Wallenberg Centre for Molecular and Translational Medicine, and the Swedish Research Council.